Literature DB >> 1587616

The glycerolipid receptor for Helicobacter pylori (and exoenzyme S) is phosphatidylethanolamine.

C A Lingwood1, M Huesca, A Kuksis.   

Abstract

We have previously shown that Helicobacter pylori specifically binds to a glycerolipid species preferentially found in the antrum of the human stomach. We now show by high-pressure liquid chromatographic analysis that this species is a form of phosphatidylethanolamine and that H. pylori specifically binds to bona fide phosphatidylethanolamine as detected by a thin-layer chromatogram overlay procedure. Considerable variation in the binding of H. pylori to phosphatidylethanolamine from different sources was observed, however, suggesting the importance of the nature of the long-chain hydrophobic moiety. A similar binding specificity was shown by exoenzyme S from Pseudomonas aeruginosa, consistent with our hypothesis that that an exoenzyme S-like adhesin is responsible for the binding of H. pylori to its lipid receptors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1587616      PMCID: PMC257183          DOI: 10.1128/iai.60.6.2470-2474.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

1.  Identification of glycolipid receptors for Helicobacter pylori by TLC-immunostaining.

Authors:  T Saitoh; H Natomi; W L Zhao; K Okuzumi; K Sugano; M Iwamori; Y Nagai
Journal:  FEBS Lett       Date:  1991-05-06       Impact factor: 4.124

Review 2.  Localization of red cell membrane constituents.

Authors:  R F Zwaal; B Roelofsen; C M Colley
Journal:  Biochim Biophys Acta       Date:  1973-09-10

3.  Pseudomonas aeruginosa exoenzyme S is an adhesion.

Authors:  N R Baker; V Minor; C Deal; M S Shahrabadi; D A Simpson; D E Woods
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

4.  Influence of soluble haemagglutinins on adherence of Helicobacter pylori to HEp-2 cells.

Authors:  J A Armstrong; M Cooper; C S Goodwin; J Robinson; S H Wee; M Burton; V Burke
Journal:  J Med Microbiol       Date:  1991-03       Impact factor: 2.472

5.  Chlamydia trachomatis and Chlamydia pneumoniae bind specifically to phosphatidylethanolamine in HeLa cells and to GalNAc beta 1-4Gal beta 1-4GLC sequences-found in asialo-GM1 and asial-GM2.

Authors:  H C Krivan; B Nilsson; C A Lingwood; H Ryu
Journal:  Biochem Biophys Res Commun       Date:  1991-03-29       Impact factor: 3.575

6.  Helicobacter pylori infection in intestinal- and diffuse-type gastric adenocarcinomas.

Authors:  J Parsonnet; D Vandersteen; J Goates; R K Sibley; J Pritikin; Y Chang
Journal:  J Natl Cancer Inst       Date:  1991-05-01       Impact factor: 13.506

7.  Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii.

Authors:  A Nomura; G N Stemmermann; P H Chyou; I Kato; G I Perez-Perez; M J Blaser
Journal:  N Engl J Med       Date:  1991-10-17       Impact factor: 91.245

8.  Helicobacter pylori infection and the risk of gastric carcinoma.

Authors:  J Parsonnet; G D Friedman; D P Vandersteen; Y Chang; J H Vogelman; N Orentreich; R K Sibley
Journal:  N Engl J Med       Date:  1991-10-17       Impact factor: 91.245

9.  Glycolipid receptor binding specificity of exoenzyme S from Pseudomonas aeruginosa.

Authors:  C A Lingwood; M Cheng; H C Krivan; D Woods
Journal:  Biochem Biophys Res Commun       Date:  1991-03-29       Impact factor: 3.575

10.  Binding of verocytotoxin 1 to its receptor is influenced by differences in receptor fatty acid content.

Authors:  A Pellizzari; H Pang; C A Lingwood
Journal:  Biochemistry       Date:  1992-02-11       Impact factor: 3.162

View more
  29 in total

1.  Acidic pH changes receptor binding specificity of Helicobacter pylori: a binary adhesion model in which surface heat shock (stress) proteins mediate sulfatide recognition in gastric colonization.

Authors:  M Huesca; S Borgia; P Hoffman; C A Lingwood
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Low prevalence of Helicobacter pylori infection in patients with hamartomatous fundic polyps.

Authors:  N Sakai; M Tatsuta; R Hirasawa; H Iishi; M Baba; Y Yokota; F Ikeda
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

Review 3.  Immunopathology of Helicobacter pylori infection and disease.

Authors:  S J Czinn; J G Nedrud
Journal:  Springer Semin Immunopathol       Date:  1997

4.  Helicobacter pylori-binding nonacid glycosphingolipids in the human stomach.

Authors:  Chunsheng Jin; Angela Barone; Thomas Borén; Susann Teneberg
Journal:  J Biol Chem       Date:  2018-09-19       Impact factor: 5.157

5.  Adherence to lipids and intestinal mucin by a recently recognized human pathogen, Campylobacter upsaliensis.

Authors:  F A Sylvester; D Philpott; B Gold; A Lastovica; J F Forstner
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

6.  Characterization of an acidic-pH-inducible stress protein (hsp70), a putative sulfatide binding adhesin, from Helicobacter pylori.

Authors:  M Huesca; A Goodwin; A Bhagwansingh; P Hoffman; C A Lingwood
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

7.  In vitro binding of Helicobacter pylori to monohexosylceramides.

Authors:  M Abul-Milh; D Barnett Foster; C A Lingwood
Journal:  Glycoconj J       Date:  2001-03       Impact factor: 2.916

8.  Adherence of Helicobacter pylori to primary human gastrointestinal cells.

Authors:  M Clyne; B Drumm
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

9.  Helicobacter pylori and complex gangliosides.

Authors:  Niamh Roche; Jonas Angström; Marina Hurtig; Thomas Larsson; Thomas Borén; Susann Teneberg
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

10.  Effect of rebamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells.

Authors:  S Hayashi; T Sugiyama; K Amano; H Isogai; E Isogai; M Aihara; M Kikuchi; M Asaka; K Yokota; K Oguma; N Fujii; Y Hirai
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.